Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence

Liver Transplantation

Volumn 17, Issue 6, 2011, Pages 685-694

  Ghabril, Marwan ^a   Dickson, Rolland C ^b   Krishna, Murli ^c   MacHicao, Victor ^d   Aranda Michel, Jaime ^c   Bonatti, Hugo ^e   Nguyen, Justin H ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PREDNISONE; RAPAMYCIN; RIBAVIRIN; TACROLIMUS;

ADULT; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DISEASE FREE SURVIVAL; DONOR; EXPLANTED LIVER INFLAMMATORY GRADE; FEMALE; FOLLOW UP; HEPATITIS C; HISTOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECIDIVISM; RECURRENT DISEASE; RETROSPECTIVE STUDY; SCORING SYSTEM; UNIVARIATE ANALYSIS; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOPSY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; KAPLAN-MEIER ESTIMATE; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79957739213     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22250     Document Type: Article

References (47)

1. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR., The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896. (Pubitemid 34267271)
2. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820. (Pubitemid 26099603)
3. Carmiel-Haggai M, Fiel MI, Gaddipati HC, Abittan C, Hossain S, Roayaie S, et al. Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl 2005; 11: 1567-1573. (Pubitemid 43072635)
4. Gane EJ., The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (Suppl 2): S36-S44.
5. Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13: 975-983. (Pubitemid 47163189)
6. Dickson RC, Caldwell SH, Ishitani MB, Lau JY, Driscoll CJ, Stevenson WC, et al. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation 1996; 61: 701-705. (Pubitemid 26097228)
7. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77: 84-92. (Pubitemid 38116877)
8. Berenguer M, Prieto M, Cõrdoba J, Rayõn JM, Carrasco D, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28: 756-763. (Pubitemid 28223478)
9. Razonable RR, Burak KW, van Cruijsen H, Brown RA, Charlton MR, Smith TF, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002; 35: 974-981. (Pubitemid 35178315)
10. Watt KD, Lyden ER, Gulizia JM, McCashland TM., Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 2006; 12: 134-139.
11. Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Cammà C, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007; 13: 733-740. (Pubitemid 46796545)
12. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009; 9: 1406-1413.
13. Ben-Ari Z, Tambur AR, Pappo O, Sulkes J, Pravica V, Hutchinson I, et al. Platelet-derived growth factor gene polymorphism in recurrent hepatitis C infection after liver transplantation. Transplantation 2006; 81: 392-397. (Pubitemid 43255725)
14. Ben-Ari Z, Pappo O, Druzd T, Sulkes J, Klein T, Samra Z, et al. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine 2004; 27: 7-14. (Pubitemid 38780932)
15. Wasmuth HE, Tag CG, Van de Leur E, Hellerbrand C, Mueller T, Berg T, et al. The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. Hepatology 2009; 49: 775-780.
16. Eid AJ, Brown RA, Paya CV, Razonable RR., Association between toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus. Transplantation 2007; 84: 511-516. (Pubitemid 47312163)
17. Terrault NA, Berenguer M., Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192-1204. (Pubitemid 44194586)
18. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
19. Batts KP, Ludwig J., Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-1417.
20. Tzakis A, Todo S, Starzl TE., Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg 1989; 210: 649-652. (Pubitemid 19271943)
21. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-663.
22. Charlton M, Ruppert K, Belle SH, Bass N, Schafer D, Wiesner RH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004; 10: 1120-1130. (Pubitemid 39248409)
23. Schott E, Witt H, Neumann K, Bergk A, Halangk J, Weich V, et al. Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy. J Viral Hepat 2008; 15: 71-78. (Pubitemid 350243584)
24. Schott E, Witt H, Neumann K, Taube S, Oh DY, Schreier E, et al. A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol 2007; 47: 203-211. (Pubitemid 47021254)
25. Manohar K, Suneetha PV, Sukriti, Pati NT, Gupta AC, Hissar S, et al. Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients. Hepatol Int 2009; 3: 371-377.
26. Haas SL, Weiss C, Bugert P, Gundt J, Witt H, Singer MV, et al. Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response. J Clin Immunol 2009; 29: 620-628.
27. Hennig BJ, Frodsham AJ, Hellier S, Knapp S, Yee LJ, Wright M, et al. Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. Liver Int 2007; 27: 1134-1143. (Pubitemid 47399449)
28. Ryan EJ, Dring M, Ryan CM, McNulty C, Stevenson NJ, Lawless MW, et al. Variant in CD209 promoter is associated with severity of liver disease in chronic hepatitis C virus infection. Hum Immunol 2010; 71: 829-832.
29. Wiederholt T, von Westernhagen M, Zaldivar MM, Berres ML, Schmitz P, Hellerbrand C, et al. Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C. Hum Immunol 2008; 69: 861-866.
30. Wasmuth HE, Zaldivar MM, Berres ML, Werth A, Scholten D, Hillebrandt S, et al. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol 2008; 48: 208-215.
31. McIlroy D, Théodorou I, Ratziu V, Vidaud D, Pellet P, Debré P, Poynard T., FAS promoter polymorphisms correlate with activity grade in hepatitis C patients. Eur J Gastroenterol Hepatol 2005; 17: 1081-1088. (Pubitemid 41424002)
32. Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007; 46: 297-306. (Pubitemid 47344763)
33. Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009; 50: 1038-1044.
34. Brown RA, Gralewski JH, Eid AJ, Knoll BM, Finberg RW, Razonable RR,. R753Q single-nucleotide polymorphism impairs toll-like receptor 2 recognition of hepatitis C virus core and nonstructural 3 proteins. Transplantation 2010; 89: 811-815.
35. Li Y, Chang M, Abar O, Garcia V, Rowland C, Catanese J, et al. Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol 2009; 51: 750-757.
36. Weston SJ, Leistikow RL, Reddy KR, Torres M, Wertheimer AM, Lewinsohn DM, et al. Reconstitution of hepatitis C virus-specific T-cell-mediated immunity after liver transplantation. Hepatology 2005; 41: 72-81. (Pubitemid 40068845)
37. Rosen HR, Doherty DG, Madrigal-Estebas L, O'Farrelly C, Golden-Mason L., Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence. Liver Transpl 2008; 14: 31-40. (Pubitemid 351167986)
38. Boccato S, Pistis R, Noventa F, Guido M, Benvegnu L, Alberti A., Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat 2006; 13: 297-302.
39. Bataller R, North KE, Brenner DA., Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 37: 493-503. (Pubitemid 36258768)
40. Ward SC, Schiano TD, Thung SN, Fiel MI., Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant. Liver Transpl 2009; 15: 1826-1833.
41. Sampson MA, Khettry U, Gordon FD, Pomposelli JJ, Pomfret EA., Explant periseptitis or inflammation >2 is strongly associated with clinically significant hepatitis C (HCV) recurrence after liver tx (LTx). Liver Transpl 2009; 15: S94-S95.
42. Rifai K, Sebagh M, Karam V, Saliba F, Azoulay D, Adam R, et al. Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol 2004; 41: 446-453. (Pubitemid 39158754)
43. Terrault NA., Hepatitis C therapy before and after liver transplantation. Liver Transpl 2008; 14 (Suppl 2): S58-S66.
44. Selzner N, Renner EL, Selzner M, Adeyi O, Kashfi A, Therapondos G, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88: 1214-1221.
45. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006; 44: 1675-1684. (Pubitemid 44953672)
46. Berenguer M, Royuela A, Zamora J., Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13: 21-29. (Pubitemid 46099970)
47. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008; 14: 512-525. (Pubitemid 351524408)